Link Archives - Corcept Therapeutics

MONARCH: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH)

January 8, 2024

Alkhouri et al. • 2024 • NASH-TAG 2024 Congress

Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)

January 8, 2024

Alkhouri et al. • 2024 • NASH-TAG 2024 Congress

Difficult-to-Control Diabetes: Is Cortisol at Play?

January 8, 2024

• 2023 • Roundtable Discussion

Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)

November 13, 2023

Alkhouri et al. • 2023 • AASLD 2023 Congress

ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer

November 6, 2023

Lorusso et al. • 2023 • IGCS 2023 Congress

Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

October 6, 2023

Donaldson et al. • 2023 • NEALS 22nd Annual Meeting

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

October 2, 2023

Lorusso et al. • 2023 • ESGO 2023 Congress

https://corcept.com/wp-content/uploads/2023/01/ENCALS2023-1.pdf

July 13, 2023

Donaldson et al. • 2023 • ENCALS Meeting 2023

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

July 6, 2023

Simeoli et al. • 2023 • Italian Society of Endocrinology National Congress 2023

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

June 27, 2023

Colombo et al. • 2023 • Journal of Clinical Oncology

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices